Recent advances in treatment of patients with castration-resistant prostate cancer after docetaxel failure.
- Author:
Bi-de CHEN
1
;
Shi-cheng YU
1
;
Gong-hui LI
1
Author Information
1. Department of Urology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou 310016,China.
- Publication Type:Journal Article
- MeSH:
Bone Neoplasms;
drug therapy;
secondary;
Drug Resistance, Neoplasm;
Humans;
Male;
Prostatic Neoplasms, Castration-Resistant;
drug therapy;
pathology;
Taxoids;
therapeutic use
- From:
Journal of Zhejiang University. Medical sciences
2014;43(1):115-118
- CountryChina
- Language:Chinese
-
Abstract:
The standard first-line treatment of castration-resistant prostate cancer (CRPC) is docetaxel-based chemotherapy. However, CRPC may not respond to docetaxel due to drug resistance or other causes. Several new therapeutic agents have been developed, some of which are approved by FDA or on clinical trials. The mechanisms of action of these agents include stabilizing microtubules, inhibiting hormone synthesis, blocking androgen receptor, bone targeting or immune regulation. In this article we review the novel therapeutic options for CPRC after docetaxel failure.
